Navigation Links
Cybrexa Therapeutics Appoints Vishwas Paralkar, Ph.D. as Chief Scientific Officer
Date:9/20/2017

Cybrexa Therapeutics, a start-up cancer therapeutics company, announced today that it has appointed Vishwas Paralkar to the role of chief scientific officer. In this role, Dr. Paralkar will lead the development of Cybrexa’s tumor targeting technology. He will report to Cybrexa’s president and CEO, Per Hellsund.

“I was impressed with Cybrexa’s revolutionary technology and excellent leadership team,” Dr. Paralkar said. “The team has had multiple past successes and I am excited to bring this technology to market.”

Dr. Paralkar has more than 20 years of experience in drug development, and brings extensive drug discovery expertise and knowledge to the team. He joins Cybrexa from Karos, Inc., where he was recently the chief scientific officer. Prior to that, he held numerous senior level positions at Pfizer. Vishwas is a very experienced drug developer responsible for submitting 8 INDs (including both small and large molecules) and one drug approval.

Hellsund commented, “We are very pleased to have Vishwas join our team. We are confident that his leadership and breadth of drug development experience will enable us to move our technology from the research stage into the clinic.”

Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors and DNA damaging agents (TSDs) that directly target the tumor microenvironment. This approach will both improve the efficacy while at the same time reduce toxicity of existing cancer drugs. The Company has made significant progress since it’s inception and now has several drug candidates that are being run through its in vitro and in vivo screening platform. The objective is to have at least one of it’s TSDs ready for a phase I clinical trial within two years.

About Cybrexa:

Cybrexa was founded by successful entrepreneurs Hellsund, Kevin Didden and Kevin Rakin, who most recently built and successfully exited Cyvek, Inc. Hellsund serves as the President and CEO, and Didden and Rakin serve as board members. Additional members of the founding team include Ranjit Bindra, M.D., Ph.D., and Peter Glazer, M.D., Ph.D., from the Yale School of Medicine. Bindra and Glazer are both physician-scientists and world-renowned experts in DNA repair. Their work has been published in numerous high-impact journals, including Science, Nature, and Science Translational Medicine.

For more information about Cybrexa, please call 860-717-2731 or visit us on the web at http://www.cybrexa.com

Read the full story at http://www.prweb.com/releases/2017/09/prweb14715217.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cybrexa Therapeutics Secures $6 Million in Series B Financing
2. Renova Therapeutics co-founder awarded highest research honor by the U.S. Department of Veterans Affairs
3. Lotus Clinical Research Executive to Present on Opioid Sparing Endpoints at 11th Annual Pain & Migraine Therapeutics Summit
4. Former VP of Clinical Pharmacology at Nektar Therapeutics, Michael A. Eldon, PhD, FCP, Joins NDA Partners as Expert Consultant
5. United Therapeutics Corporation Reports Second Quarter 2017 Financial Results
6. Myonexus Therapeutics, Inc. Launches to Develop Pioneering, Clinical-Stage Gene Therapies Targeting Limb-Girdle Muscular Dystrophies
7. Industry leaders join Renova Therapeutics to lead preclinical programs into clinical development
8. United Therapeutics Announces $250 Million Share Repurchase Program
9. Arrowhead Publishers’ 11th Annual Pain and Migraine Therapeutics Summit Set to Take Place This Fall in San Diego, CA
10. Open Therapeutics and the Center for Advancing Innovation Form Partnership
11. Brainstorm Cell Therapeutics to Present at ARMs 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research ... Inc. has been selected for membership in ARCS Alumni Hall of Fame ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its ... 2018 in San Francisco, CA. The Summit brings together current and former FDA office ... directors and government officials from around the world to address key issues in device ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... March 24, 2017 The Controller General of Immigration ... Abdulla Algeen have received the prestigious international IAIR Award for ... Continue Reading ... ... Deputy Controller Abdulla Algeen (small picture on the right) have received the ...
Breaking Biology News(10 mins):